At a glance
- Originator Inpharzam Ricerche S.A.
- Class Anti-inflammatories
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 20 Sep 2002 Preclinical trials in Asthma in Switzerland (unspecified route)